Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 3/20 | 0.45 |
| ▸ | AURKA | O14965 | 7/20 | 0.44 |
| ▸ | CDK4 | P11802 | 5/20 | 0.44 |
| ▸ | CDK1 | P06493 | 2/20 | 0.44 |
| ▸ | INSR | P06213 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | FLT1 | P17948 | 1/20 | 0.44 |
| ▸ | FLT4 | P35916 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | CDK7 | P50613 | 1/20 | 0.44 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 10/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.42 |
| ▸ | USP2 | O75604 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8513398 | 0.80 | AURKA (0.46) | TTKAURKACDK4CDK1INSR | |
| SCHEMBL586028 | 0.77 | AURKA (0.46) | TTKAURKACDK4CDK1INSR | |
| SCHEMBL586596 | 0.77 | AURKA (0.40) | TTKAURKACDK4CDK1INSR | |
| SCHEMBL8513406 | 0.76 | MTNR1A (0.40) | TTKAURKACDK4CDK1INSR | |
| SCHEMBL4202568 | 0.74 | CDK4 (0.47) | TTKAURKACDK4CDK1INSR | |
| SCHEMBL29287418 | 0.73 | AURKA (0.46) | TTKAURKACDK4CDK1INSR | |
| SCHEMBL29779671 | 0.73 | AURKA (0.46) | TTKAURKACDK4CDK1INSR | |
| SCHEMBL29287417 | 0.71 | TTK (0.46) | TTKAURKACDK4CDK1INSR | |
| SCHEMBL30480564 | 0.70 | AURKA (0.41) | TTKAURKACDK4CDK1INSR | |
| SCHEMBL27033337 | 0.70 | AURKA (0.41) | TTKAURKACDK4CDK1INSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9593108-B2 | Compounds and methods for antiviral treatment | PTC THERAPEUTICS, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-20120135999-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | PTC THERAPEUTICS, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120135999-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | PTC THERAPEUTICS, INC. (US) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135999-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | EIF2AK2, MAVS, ZC3HAV1 | TTK 3989/4885AURKA 2717/4885CDK4 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.